# Pembrolizumab After Radiation Therapy and Chemotherapy in Limited Stage Small Cell Lung Cancer

> **NCT06140407** · PHASE2 · TERMINATED · sponsor: **Vanderbilt-Ingram Cancer Center** · enrollment: 1 (actual)

## Conditions studied

- Limited Stage Lung Small Cell Carcinoma
- Stage I Lung Cancer
- Stage II Lung Cancer
- Stage III Lung Cancer

## Interventions

- **DRUG:** Cisplatin
- **DRUG:** Carboplatin
- **DRUG:** Etoposide
- **BIOLOGICAL:** Pembrolizumab
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Positron Emission Tomography
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** Biospecimen Collection
- **RADIATION:** Radiation Therapy

## Key facts

- **NCT ID:** NCT06140407
- **Lead sponsor:** Vanderbilt-Ingram Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-02-14
- **Primary completion:** 2025-05-27
- **Final completion:** 2025-05-27
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Low accrual and Merck discontinuing funding and drug supply
- **Last updated:** 2025-06-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06140407

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06140407, "Pembrolizumab After Radiation Therapy and Chemotherapy in Limited Stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06140407. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*